Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Health Network, Toronto
With
Princess Margaret Hospital, Canada
Age
18–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
UICC TNM stage 0 (i.e. in situ disease), 1 or 2 breast cancer patients treated with conservative surgery and adjuvant radiotherapy with chronic breast pain or tenderness, with or without fibrosis, within 3 months to 3 years following completion of radiotherapy
Age 18 to 75 years of age
Chronic symptoms localised to the breast treated with radiation, i.e. any one or more of the following- pain (not attributable to infection) or tenderness with or without associated oedema, fibrosis, necrosis or ulceration.
Breast pain (maximum in the previous 24 hours) measurable on a Linear Analogue Scale with a length of 3cm or greater
Prior treatment with radiation to the affected area i.e. in tangential breast fields or boost area
Radiation completed at least 3 months and no longer than 3 years prior to study entry
Informed consent
You may not be if
Active cellulitis in the breast
Active malignant disease
Any medical illness or condition judged likely by the local investigator to preclude safe administration of protocol treatment
Contraindication to treatment with pentoxifylline (i.e. previously exhibited intolerance to pentoxifylline or other xanthines such as caffeine, theophylline or theobromine; recent cerebral and/or retinal haemorrhage; ischaemic heart disease; hypotension
Pregnant or lactating women
Clareo Health | The Use of Pentoxifylline and Vitamin E in the Treatment of Chronic Breast Pain
